Organization | Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. Report issue

For profit Phase 1

Founded: San Diego CA United States (2015)

Organization Overview

First Clinical Trial

2017

NCT03288493

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Poseida Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (6)

autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)

bcma-pd1-cart cell (1 trial)

p-bcma-allo1 car-t cells (1 trial)

p-muc1c-allo1 car-t cells (1 trial)

psma car-t cell (1 trial)

tacrolimus (prograf) (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Genital Neoplasms, Male (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms by Histologic Type (Phase 1)

Neoplasms by Site (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Prostatic Diseases (Phase 1)

Prostatic Neoplasms (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Urogenital Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 6
# of Trial APIs: 6